Peptides and testosterone often appear together in scientific studies and online discussions because some peptide signals participate in the regulation of the hormonal system associated with development. However, this biological association does not mean that all peptides increase testosterone levels, that they form a single category of „hormone-boosting substances,” or that an increase in testosterone concentration automatically translates into improved symptoms, fertility, sexual function, strength, body composition, or general health status.
Studies involving humans clearly show why such broad claims are difficult to justify. Different peptide-related interventions can affect the hormonal system in opposite directions, depending on the specific molecule, receptor, population being studied, exposure time, and experimental conditions.
In a small study involving humans, kisspeptin increased selected parameters of reproductive hormones in men with type 2 diabetes and low testosterone levels. In turn, in studies of the modified analog of kisspeptin TAK-448 and a peptide antagonist of gonadotropin-releasing hormone, namely acylin, suppression of testosterone was observed under certain experimental conditions.[1][2][3]
These seemingly opposing results do not necessarily have to contradict each other. They rather show that the very term „peptide” says very little about the direction of action of the endocrine system, unless it is known what molecule and what biological target is being referred to.
From a scientific point of view, therefore, one should ask a more precise question: which molecule was being studied, on which receptor or pathway was it acting, in what population, for what length of time, under what exposure scheme, and what biological or clinical outcome was actually measured?
In this article, we discuss these differences and explain what peptide and testosterone studies can actually show and what cannot be concluded from them. This is an educational review of the research, not a guide on choosing, combining, dosing, or administering substances that affect the hormonal system.
Why do peptides and hormones appear in the same studies?
Peptides and hormones often occur together in the scientific literature because the human hormonal system is based on many interacting signaling molecules.
Some of these signals have a peptide structure, while others belong to completely different chemical classes.
The fact that one substance affects another does not mean that they are chemically the same.
This distinction is particularly important because in commercial communications one may encounter terms such as „hormonal peptide,” „testosterone peptide,” or „hormone-balancing peptide,” often without explaining what biological mechanism is actually being studied.
Testosterone is a steroid hormone, not a peptide
Testosterone is not a peptide.
Peptides consist of amino acid residues linked by peptide bonds. Testosterone, however, is a steroid hormone and has a fundamentally different chemical structure.
The common occurrence of testosterone and peptides in studies is due to interactions between different biological signaling systems, not to a chemical similarity.
The hormonal system involved in development includes several levels of regulation.
At the hypothalamic level, the hormone releasing gonadotropins, namely GnRH, influences the pituitary gland to secrete gonadotropins. These signals, including luteinizing hormone (LH) and follicle-stimulating hormone (FSH), participate in regulating gonad function and the production of sex hormones.
Kisspeptin acts even higher in this system and is an important regulator of the signaling network associated with development.
The peptide can therefore indirectly affect testosterone through a change in signaling in another part of the hormonal axis.
However, this does not mean that the peptide itself is testosterone.
It also does not mean that every peptide has a confirmed effect on its level.
A peptide that acts on a completely different receptor may not have a significant effect on the hormonal system associated with development.
The very term „peptide” therefore does not allow us to predict whether testosterone will increase, decrease, remain unchanged, or change in different ways over time.
Is testosterone a peptide?
No. Testosterone is a steroid hormone, whereas peptides are composed of amino acids linked by peptide bonds. Both groups appear together in studies because some peptide signals can influence the production of reproductive hormones. Studies of kisspeptin are an example of such regulatory relationship.[1] However, the peptide that affects testosterone levels remains chemically and biologically distinct from testosterone itself.
Stimulating the hormonal pathway and blocking it are two different actions
Peptide interventions related to the hormonal system can act in fundamentally different ways.
An agonist activates a receptor or a specific signaling pathway, whereas an antagonist blocks its activation.
Even this division does not explain everything, because biological systems possess mechanisms of regulation and adaptation. The effect of a short stimulus to a receptor can differ significantly from the effects of prolonged or repeated stimulation.
A good example is a study involving acyline, a peptide antagonist of GnRH.
After administration of this intervention, suppression of gonadotropins and testosterone was observed in healthy young men.[3]
This result directly contradicts the simplified assumption that any substance identified as a peptide and associated with reproductive hormones must increase testosterone levels.
The studies of TAK-448 show even greater complexity in this matter.
TAK-448 is an experimental modified analog of kisspeptin. Although kisspeptin signaling can initially stimulate the activity of the reproductive axis, longer exposure to TAK-448 in the first human studies led to testosterone suppression. [2]
The most important conclusion is therefore not that kisspeptin always increases or always decreases testosterone.
The significance is given by the specific molecule, the receptor behavior, the nature and duration of the exposure, and the biological adaptation.
Short-term hormonal responses should not be automatically translated into a statement regarding the long-term impact on hormones.
Does kisspeptin always increase testosterone?
No. Available studies do not indicate a universal or sustained stimulating effect. Short-term stimulation associated with kisspeptin and longer exposure to a modified analog may lead to other endocrine patterns. In the TAK-448 studies, among other things, long-term suppression of testosterone was observed after the initial stimulatory response under certain conditions. [2] Therefore, the specific molecule, the method and duration of exposure, the population studied, and the organism’s adaptation are important factors.
Different hormonal axes should not be combined with each other
Substances related to growth hormone are often discussed together with compounds affecting the reproductive system, especially in commercial categories concerning peptides.
From a scientific point of view, however, these systems must be considered separately.
An intervention that increases growth hormone does not simultaneously increase testosterone levels.
The change in the level of insulin-like growth factor 1, or IGF-1, in itself does not confirm an improvement in fertility, libido, reproductive function, or testosterone levels.
A good example is ibutamoren, known as MK-677.
MK-677 is sometimes grouped with peptides in online discussions, even though it is a non-peptidic mimic of growth hormone.
Studies in older adults primarily concerned the growth hormone system and body composition parameters.[4] They do not prove that MK-677 is a „testosterone peptide” or that any substance advertised as a „growth peptide” is a proven intervention affecting testosterone.
It is therefore important to distinguish between the intended effect on a specific hormonal pathway and a broad marketing category that combines several unrelated substances.
Any claim regarding hormones requires data relating to a specific hormone and a specific result.
„Hormonal balance” is not an accurate scientific endpoint
The term „hormonal balance” is often used because it is broad and comprehensive, but it is difficult to evaluate it scientifically without indicating specific hormones and results.
An increase or decrease in the concentration of one hormone does not indicate the restoration of the balance of the entire endocrine system.
Hormones act within a network of feedback loops.
The increase in a specific hormone may be desirable in one clinical context, but undesirable or irrelevant in another.
Similarly, its reduction can in certain situations constitute a deliberate therapeutic or experimental effect.
Therefore, one cannot accept the simple principle that „more” always means „better”.
A scientifically useful statement should indicate what has actually been measured.
The study may, for example, assess LH secretion, total serum testosterone, free testosterone, pulsatile gonadotropin secretion, or a validated symptom score.
Without a clearly defined population, measurement, a control group, and a final endpoint, the term „balancing hormones” remains too imprecise to be reliably evaluated.
The hormonal result and the clinical result are two different levels of evidence.
One of the most important distinctions in testosterone studies is the difference between demonstrating a change in a laboratory parameter and demonstrating a significant clinical outcome.
Measurement of hormones can show that a given biological pathway has reacted.
However, they do not automatically report whether the participants experienced a significant improvement in health or functioning.
The concentration of testosterone in the blood is an indirect result
A good example is a small proof-of-concept study regarding kisspeptin-10.
Five men with type 2 diabetes and mild biochemical hypogonadism participated in it, along with a healthy control group. In some analyses, only four participants with the disorder were included. After exposure to kisspeptin-10, an increase in LH and testosterone was observed.[1]
This is real evidence involving people that indicates an endocrine response.
However, very small sample size and a strictly defined population are crucial for interpretation.
The study does not prove that kisspeptin leads to a sustained increase in testosterone in the general population of men.
It does not confirm a long-term improvement in symptoms.
It does not show an improvement in fertility.
It does not prove an increase in muscle strength or athletic performance.
It also does not allow for determining long-term safety.
It answers a much narrower question: did the hormonal system associated with development react to kisspeptin under certain experimental conditions?
Such a distinction prevents the result of a mechanistic or laboratory approach from being transformed into a broader therapeutic or sporting claim.
Does a change in hormone levels mean a clinical benefit?
No. A change in hormone confirms the biological response, whereas clinical benefit requires an improvement in an outcome that is relevant to the well-being, functioning, or health of the individual. A small kisspeptin-10 study showed changes in LH and testosterone, but did not confirm a sustained improvement in symptoms, fertility, strength, or athletic performance.[1] This is valuable proof of concept that should not be extrapolated to results not directly tested.
The measurement time, repeatability and quality of the marking are important
Testosterone is not a constant biological parameter.
The concentration measured in the blood sample depends partly on the moment and conditions of the sampling.
The interpretation of the studies therefore requires something more than a simple comparison of one initial result with one later measurement.
The sampling conditions should be as uniform as possible.
The analytical method used should be appropriate for the measured range of concentrations.
Repeated measurements, however, help to distinguish the ongoing change from normal biological variability or a short-term response.
The Endocrine Society guidelines emphasize the importance of symptoms, reliable methods of measuring and confirming low testosterone levels, rather than relying on a single isolated result to make a diagnosis.[5]
When evaluating the studies, it is therefore necessary to check whether the sampling conditions were uniform, whether appropriate analytical methods were used, whether baseline variability was taken into account, and whether the observed change persisted beyond the short-lived peak.
These are the rules for interpreting evidence, not instructions for performing tests or making diagnoses on your own.
Is one testosterone measurement enough to determine that the intervention worked?
No. The result may vary depending on biological conditions, measurement time, analytical method used, health status, and other factors. The Endocrine Society guidelines emphasize proper clinical context, reliable measurement, and confirmation of the result rather than relying on a single value to draw conclusions.[5] Even after confirming a real change in testosterone levels, the question remains: has the significant clinical outcome improved?
Total and free testosterone are different measurements
Another source of misunderstanding is the assumption that any result regarding testosterone accurately describes the same biological phenomenon.
Total testosterone includes testosterone circulating in the blood in various binding states.
Free testosterone means its non-bound fraction.
Changes in the concentration of binding proteins can affect the relationship between total and free testosterone.
An increase in total testosterone does not therefore automatically mean that free testosterone has increased to the same extent.
None of these parameters alone describes all aspects of androgenic activity in tissues.
Therefore, both the labeling method and the biological context are important.
The Endocrine Society guidelines, which emphasize the proper assessment of total and, when appropriate, free testosterone, show why a claim based solely on an undefined „testosterone level” can be incomplete.[5]
The review of the evidence should present the parameter that was actually used in the study, rather than converting every androgen-related result into a general statement about testosterone.
Can total and free testosterone be treated interchangeably?
No. They describe different aspects of circulating testosterone. Changes in binding proteins can alter the ratio between the total and free fractions of the hormone. [5] The scientific claim should therefore specify which parameter was actually measured, rather than assuming that any change in total testosterone means an identical change in free testosterone or androgenic activity in the tissues.
Statistical significance does not automatically mean significant benefit
Statistically detectable changes in testosterone levels can be biologically interesting while remaining short-lived, minor, or unrelated to the outcome perceived by the patient.
On the other hand, a very small study may not allow for a precise answer to an important clinical question, even if the observed change seems large.
The size of the effect is therefore important.
The uncertainty of this estimate is also significant.
The duration of the change is also important.
Researchers should, as far as possible, distinguish short-term hormonal peaks from persistent changes and determine the most important clinical outcomes in advance.
The p value alone does not inform whether participants actually experienced an improvement or whether the change has practical clinical significance.
The same principle applies when the laboratory result moves into the reference range.
In the appropriate context, this may be clinically significant, but in itself it does not prove an improvement in sexual function, fertility, physical fitness, mood, body composition, or quality of life.
Reproductive signaling, testosterone, symptoms, fertility and fitness are separate results
In testosterone studies, several related results may appear, but each answers a different question.
Changes in LH or FSH indicate activity within the reproductive signaling system. They do not in themselves indicate an improvement in fertility or the disappearance of symptoms.
The change in serum testosterone concentration is an endocrine-mediated result. It does not confirm a universal clinical benefit.
A change in the validated result regarding symptoms indicates a change in those specific symptoms, but it does not yet prove that testosterone was the cause.
The semen analysis can provide information about selected characteristics related to development, but it does not guarantee fertilization, pregnancy, or a live birth.
Body composition measurements can show a change in estimated amounts of lean or fat tissue, but do not automatically confirm greater strength, better sexual function, or fertility.
Similarly, improvement in a specific strength or fitness test means improvement in that very task. It does not automatically confirm benefits in any other area of physiology.
A well-designed clinical trial can combine several of these levels.
However, if only one of them is evaluated, the summary of the evidence should not omit the missing stages and present the expected final result as if it had also been demonstrated.
Libido is not a measure of testosterone
Sexual desire is influenced by numerous biological, psychological, interpersonal, neurological, and situational factors.
The testosterone level alone does not show how a participant experiences sexual desire.
A study formulating a claim regarding libido should therefore actually measure libido, sexual functions, the associated distress, or any other appropriate outcome experienced by the participant.
In a randomized cross-over study of kisspeptin in men with hypofunctional sexual desire disorder, responses of the brain, sexual arousal, and behavioral measurements were analyzed during controlled visits.
The study included 32 men. [6]
The results support further research on the role of kisspeptin signaling in the processing of sexual stimuli.
However, they do not demonstrate a general effect that increases testosterone levels.
They also do not confirm the lasting therapeutic benefit beyond the conditions and observation period used in the study.
The observed sexual response cannot be automatically attributed solely to changes in testosterone unless the study design and measurements performed actually confirm such a causal relationship.
Does improving libido mean that testosterone levels have increased?
No. Sexual desire depends on many biological, neurological, psychological, interpersonal, and situational factors. The kisspeptin study of sexual arousal processing evaluated many neuronal, physiological, and behavioral parameters, rather than assuming that any observed sexual response simply results from increased testosterone levels.[6] Therefore, libido and endocrine parameters should be analyzed separately if the study did not show a specific causal relationship.
Brain imaging is not the same as everyday sexual functioning
Functional imaging studies can reveal differences in the brain's response during controlled experimental tasks.
Such results can be very valuable in studying biological mechanisms.
However, they are not synonymous with demonstrating a lasting improvement in sexual satisfaction, relationship functioning, stress, or quality of life.
In a cross-sectional study, the same participant may receive different interventions, which helps to reduce the influence of individual variability.
The results still refer, however, to a specific period of exposure, laboratory stimuli, tasks performed, and endpoints assessed.
The claim regarding lasting clinical benefit requires a sufficiently long period of observation and significant results reported by the patients.
An impressive brain imaging result should therefore not replace clinical evidence.
Similar interpretation principles apply to other claims related to the nervous system. In the article about Peptides and sleep, memory and brain function We explain why the results regarding biomarkers, imaging, sleep, and cognitive functions should be treated as separate endpoints.
Fertility requires a separate evaluation
Testosterone plays an important role in the physiology of the male reproductive system, but its serum concentration is not a complete measure of fertility.
Fertility studies may include sperm parameters, sperm production, functions of reproductive cells, fertilization, pregnancy, and live birth, depending on the population and the research question.
These results should be considered separately.
Even an improvement in sperm parameters does not guarantee fertilization.
Pregnancy depends on many factors affecting both partners and cannot be attributed to the concentration of testosterone in one person.
The Endocrine Society guidelines treat fertility planning as an important issue separate from correcting low testosterone levels itself.[5]
This leads to an important principle of evidence interpretation: an increase in testosterone should not automatically be presented as evidence of improved fertility.
Fertility requires its own appropriate endpoints.
The broader significance of these distinctions, including the differences between hormones, libido, fertility, pregnancy, and the reproductive life stage, is also discussed in the article about peptides for women.
Does higher testosterone mean better fertility?
No. Fertility encompasses the functioning of reproductive cells and clinical reproductive outcomes, which cannot be reduced to a single hormone marker in the blood.[5] An increase in testosterone may be a significant biological result, but demonstrating an improvement in fertility requires measurements directly related to fertility.
The hormonal response may weaken with repeated exposure
The reaction observed after the first exposure does not necessarily predict what will happen when it is repeated.
This principle is well demonstrated by the study of women with hypothalamic amenorrhea.
After kisspeptin-54, a strong initial gonadotropin response was observed, which however decreased during repeated administration in the study regimen. No significant changes in the described ultrasound parameters of reproductive activity were observed in this case.[7]
This study does not allow for direct determination of what would happen in men with other reproductive disorders or under other exposure patterns.
Its significance is primarily conceptual.
It shows that biological systems can adapt to repeated stimulation.
Therefore, a short-term endocrine response should not be automatically presented as a permanent response.
Similarly, changes in hormonal signals should not be considered evidence of the restoration of reproductive function.
The long-term behavior of a specific intervention must be examined directly.
Lean body mass, strength, testosterone and sexual functions are not the results of surrogate measures.
Body composition is another area where the results of studies are often overly generalized.
The study measuring lean mass or fat mass answers a different question than the study regarding testosterone-related symptoms, sexual desire, fertility, strength, or athletic performance.
The MK-677 study in older people provides a useful example.
An increase in lean body mass was observed, but no corresponding improvement in strength or physical function was found.[4]
Because MK-677 is a non-peptide growth hormone-releasing factor mimetic acting within the growth hormone signaling pathway, this study does not provide direct evidence regarding a peptide affecting the reproductive system.
However, it has methodological significance.
It shows that even a measurable change in the seemingly beneficial intermediate outcome does not guarantee an improvement in the function that the person ultimately depends on.
Therefore, claims promising greater muscle mass, higher testosterone, better libido, improved fertility, and greater performance require evidence for each of these elements.
One favorable laboratory or body composition result does not confirm the entire set of such claims.
In the case of claims regarding muscle mass and bodybuilding, we discuss the detailed distinction between muscle mass, body composition, strength, and sports results in an article about peptides for muscle growth and bodybuilding.
The population studied determines the scope of the evidence
The study participants determine who their results describe most directly.
An experiment of a proof-of-concept type involving men with obesity, type 2 diabetes and low testosterone does not automatically represent healthy men.
It does not automatically represent athletes.
It does not have to represent older men with another endocrine disorder either.
It also does not allow for the determination of identical effects in women.
Similarly, a study conducted in the context of prostate cancer may deliberately analyze testosterone suppression rather than its increase.
Using such a study as evidence of „raising testosterone” would mean a misinterpretation of the research question.
The first step in interpreting any study involving peptides and testosterone should therefore be to determine why the participants were included and what biological effect the researchers intended to analyze.
The same hormone can be deliberately stimulated in one research context and inhibited in another.
Can the results obtained in men with type 2 diabetes be transferred to healthy athletes?
Not directly. The kisspeptin-10 study included men with a specific metabolic and hormonal profile, and not a representative group of healthy people who trained either strength or endurance. [1] Baseline physiology, health status, level of training, and expected outcome all influence the possibility of generalizing the results. Claims regarding athletic performance in healthy athletes require studies in a suitable population.
Changes in general health status can affect hormonal results
Hormonal parameters do not function in isolation from the rest of physiology.
Body weight, acute or chronic illness, sleep, energy balance, medications used, and other health changes can all affect the results of endocrine testing.
If several factors change simultaneously during an uncontrolled intervention, the later difference in testosterone levels cannot be automatically attributed solely to the newly introduced substance.
Randomization and an appropriate comparison group help to reduce some of these problems.
Repeated, uniform measurements and a previously planned analysis further increase the reliability of the interpretations.
Observational studies can also provide valuable information, but their limitations in determining causality should remain visible.
The correlation between the natural concentration of a specific peptide and testosterone does not prove that administering this peptide will increase testosterone.
It does not therefore prove that such intervention will improve symptoms or other clinical outcomes.
Sleep is one of the factors that can appear in a broader context of physiology and hormonal measurements. However, this does not mean that the result regarding sleep can be automatically converted into a statement about testosterone. We discuss these differences in more detail in the material about peptides, snow, memory and brain function.
Short-term experiments and long-term studies answer other questions
An acute endocrinological experiment can show whether a given biological pathway responds to a specific stimulus.
A longer clinical study, however, can verify whether the response persists and whether it translates into symptoms, functioning, significant clinical outcomes, or adverse reactions.
The difference between short-term stimulation and long-term suppression observed in the TAK-448 studies shows why the exposure time cannot be treated as a minor methodological detail. [2]
It would not be scientifically justified to observe initial growth and assume that prolonged exposure must lead to even greater or more sustained growth.
Reciprocal interactions and receptor adaptation can change the response over time.
These observations help to understand the physiology of the hormonal system.
However, they should not be interpreted as instructions on how to manipulate the exposure.
Translating these results into clinical practice requires an appropriate context and evidence regarding the specific product and the specific goal.
The choice of the comparison group and the blinding influence the interpretation
The research project largely determines how reliably the observed result of a specific intervention can be attributed.
A placebo-controlled study helps distinguish the intervention effect from expectations, spontaneous variability, and changes that could have occurred without the treatment.
The study with an active comparator answers another question, because it compares the intervention with another treatment.
An uncontrolled „before and after” study has a significantly lower ability to distinguish the intervention effect from changes occurring in the background.
The masking is particularly important when the evaluated results include symptoms, satisfaction, sexual functions, energy, or other subjective experiences.
Even in blinded studies, recognizable adverse effects or physiological changes can potentially affect the participants' expectations.
The way the resignation is reported also matters.
If the analysis includes only individuals who tolerated the intervention well and completed the study, the result obtained may differ from the analysis of all the originally assigned participants.
When assessing the strength of the conclusions, it is therefore necessary to take into account the way in which the missing data are handled.
Subgroup analyses and numerous results require caution
A study measuring multiple hormones, symptoms, biomarkers, subgroups, and time points creates many possibilities for the appearance of seemingly beneficial results.
A predetermined main endpoint helps distinguish the basic research question from exploratory observations.
Analyses of subgroups require similar caution.
A statistically significant result in one subgroup and no significance in the other do not automatically prove that the groups actually react differently.
The apparent difference may result from different sample sizes, variability, or chance.
Direct statistical analysis that verifies whether the effect of the intervention differs between subgroups provides more robust data.
The same principle applies when transferring results between women and men or between different clinical populations.
The physiology of reproduction, the initial hormonal status, the characteristics of the disease, and the expected results may vary significantly.
The populations of these species should not be freely combined or compared without an appropriate research design.
Not every peptide stimulates reproductive hormones
Peptides perform very diverse biological functions.
Some activate signaling related to development.
Others block it.
Many have no established role in the regulation of testosterone at all.
Studies of acyline and TAK-448 directly show that with certain peptide or peptide-like interventions, testosterone suppression may occur. [2] [3]
Therefore, a peptide is not synonymous with a „testosterone booster”.
Hormonal stimulation should not be automatically considered to be beneficial either.
Whether the increase, decrease, or absence of a given hormone is clinically desirable depends on the specific condition and the goal of the intervention.
The available evidence also does not support the assumption that it is possible to selectively increase one desired hormone without affecting the other interacting physiological systems.
The endocrine pathways communicate with each other.
Therefore, the action and safety of a specific intervention must be studied directly, rather than being derived solely from a simplified schematic of the biological mechanism.
Do all peptides stimulate the hormonal system?
No. Peptides have very diverse biological functions. Some activate receptors, others block signaling, and many act outside the reproductive system. A good example is acylatedin, because this peptide antagonist of GnRH caused suppression of gonadotropin and testosterone in a human study [3]. Therefore, the very word „peptide” does not allow us to predict whether a given substance will increase testosterone, lower it, or have a proven effect.
The small number of reported adverse reactions does not indicate a low risk
Small early-phase studies may show few adverse effects only because a small number of people were exposed to the substance and the observation lasted for a short time.
Such projects are poorly suited to excluding rare, delayed, or specific to a particular population adverse reactions.
The study of ibutamoren in people after a hip fracture shows why mechanistic justifications should not be considered a guarantee of safety.
Despite the justification related to the achievement of growth hormone, a safety signal appeared and the study was terminated prematurely.[8]
This result applies to a specific substance, study, and population.
It should not be assumed on the basis of this that every related intervention carries the same risk.
However, it illustrates an important principle of evidence assessment: a biologically plausible mechanism is not evidence of clinical safety.
A separate issue is the risk associated with the product itself.
The name of the ingredient or the laboratory purity declaration do not automatically confirm the identity, concentration, stability, sterility, absence of impurities, or equivalence to the product used in the published clinical study.
Does a small number of reported adverse reactions mean that the substance is safe?
No. A small or short-term study may simply not include sufficient exposure to detect rare or delayed adverse effects. A study of ibutamirone following a hip fracture showed a safety signal despite a biologically plausible justification for the intervention.[8] The safety assessment should therefore consider the totality of evidence regarding the specific substance, not just a small number of adverse effects in a small study.
Clinical evidence relates to the specific investigational product
Closely related molecules should not automatically take over each other's evidence.
The publication regarding kisspeptin-10 does not independently confirm the activity of kisspeptin-54.
None of them automatically confirms the action of the modified analog TAK-448.
A commercial preparation with an uncertain composition also cannot automatically use the evidence obtained for a precisely characterized experimental preparation.
Related molecules can differ in their behavior towards the receptor, their potency, pharmacokinetics, exposure duration, and biological effect.
The same problem applies to multicomponent mixtures.
Testing a single component does not confirm the effectiveness of the entire package offered by the clinic or manufacturer just because a given substance is included in it.
The interactions between the components and the contribution of each of them remain separate research questions.
A reliable claim should indicate a specific molecule or preparation, a population, a comparator, the result, and the duration of the study.
If these characteristics do not correspond to the cited studies, the evidence is of an intermediate nature.
What can reasonably be inferred from the available research?
Available studies show that certain peptide pathways can influence the secretion of hormones related to the reproductive system under specific experimental conditions.
They also show that the direction, magnitude, and persistence of these effects can vary.
Kisspeptin-related stimulation can elicit short-term endocrine responses in certain populations.[1]
Modulated or persistent signaling associated with kisspeptin may lead to a different hormonal pattern, including suppression of testosterone under certain experimental conditions.[2]
Direct blocking of GnRH signaling with a peptide antagonist can lead to suppression of gonadotropins and testosterone.[3]
Overall, these studies show the complexity of endocrine regulation, rather than the universal properties of peptides that involve increasing testosterone levels.
They do not prove that every peptide increases testosterone.
They do not prove that short-term improvement leads to lasting clinical benefit.
They also do not prove that a higher testosterone level in itself means better fertility, libido, muscle growth, strength, athletic performance, or overall health.
Each of these results requires relevant data from human studies.
The most reliable interpretation therefore preserves the mechanism of action, the laboratory result, the clinical result, the duration of the effect, and safety as related but distinct elements of the evidence.
Frequently asked questions about peptides and testosterone
Are growth hormone and testosterone the same research target?
No. Growth hormone and testosterone belong to different hormone systems. A change in growth hormone or IGF-1 does not indicate a change in testosterone. The MK-677 study in older adults primarily focused on the growth hormone system and body composition, not on overall benefits for the reproductive system.[4] Therefore, claims should be linked to the pathway that was actually studied.
Is MK-677 a testosterone peptide?
No. MK-677, ibutamoren, is a non-peptide mimic of growth hormone. In commercial discussions and related to sports performance, it often appears alongside peptides, but by chemical definition such a designation is incorrect. In a study of older adults, an increase in lean body mass was observed without corresponding improvements in strength or function. [4] The study therefore does not make MK-677 a peptide nor does it confirm it as a testosterone therapy.
Does a change in body composition mean an improvement in sexual function?
No. Body composition and sexual function are two separate outcomes. The MK-677 study shows that the intermediate physical parameter can change without corresponding improvement in functional outcomes. [4] The claim regarding sexual function requires appropriate measurement of these functions in the appropriate population, rather than inference based on changes in lean body mass.
Does a short-term hormonal response allow to predict the long-term effect?
Not automatically. Endocrine systems can adapt, and repeated or prolonged exposure can lead to a different effect than the first exposure. In the kisspeptin study in women with hypothalamic amenorrhea, initially strong gonadotropin responses decreased during repeated exposure. [7] This study shows why the durability of the response must be examined directly.
Do changes in brain imaging confirm a lasting improvement in libido?
No. Functional imaging shows the response of the nervous system under specific experimental conditions. The kisspeptin cross-talk study provides valuable mechanistic and short-term data, but these results alone do not confirm a sustained improvement in daily sexual function. [6] Long-term clinical benefit requires appropriate outcomes reported by participants and a proper observation period.
Is the combination of peptides confirmed if the individual components have separate studies?
No. The combination of several substances creates a new intervention. Its action, interactions, exposure, and risk cannot be automatically determined by adding the results of independent studies of individual components. The different patterns of stimulation and suppression observed in kisspeptin-related studies show why a simple assumption of the summation of effects can be misleading. [1] [2] Evidence regarding combinations should include precisely that combination in the appropriate clinical context.
What question is best to ask when evaluating a claim about testosterone?
The most useful question is: did this intervention lead to a significant and lasting clinical outcome in the relevant population of people, and not just a short-term change in hormone levels? Studies of kisspeptin and acylin show that the effect on reproductive hormones can vary significantly in terms of direction and context. [1] [3] A valid conclusion should take into account the specific molecule, the population, the type of measurement, the magnitude and duration of the response, the clinical endpoint, and limitations regarding safety.
Limitations of the available evidence
When interpreting studies on peptides and testosterone, several recurring limitations must be taken into account.
The first is the diversity of the interventions themselves. „Peptide” describes a vast category of chemicals and biological agents, not just one type of treatment. Kisspeptin, GnRH antagonists, modified peptide analogues, and other signaling peptides should not be treated as if they had identical endocrine properties.
The second limitation is the specificities of the population. The results obtained in men with type 2 diabetes and biochemically low testosterone cannot be automatically transferred to healthy men, athletes, older people with other comorbidities, women, or other populations [1].
The third problem is the frequent use of indirect endocrine markers. A change in LH or testosterone can confirm biological activity, without simultaneously improving symptoms, fertility, strength, body composition, libido, or quality of life.
The fourth limitation is time. Short-term and prolonged exposure can lead to different results, as the studies of TAK-448 show particularly well. [2] Therefore, initial stimulation should not be considered as evidence of long-term stimulation.
The fifth problem is the very method of measuring testosterone itself. Total testosterone, free testosterone, binding proteins, the laboratory method used, the moment of sample collection, and natural biological variability can all influence the interpretation.
The sixth limitation is that mechanistic and imaging studies provide important biological information, but do not automatically confirm lasting benefits in daily functioning.
Seventhly, safety data may appear later than mechanistic data. Small studies and short exposure do not allow for reliably detecting rare or delayed adverse effects. [8]
Finally, the evidence relates to a specific preparation that has actually been tested. The kisspeptin-10 study does not automatically confirm the effects of kisspeptin-54, TAK-448, an unidentified commercial preparation, or a multi-component combination.
These limitations do not mean that research on peptides and the hormonal system is of little value. They merely define the limits of the conclusions that can be reasonably drawn from it.
Summary
Peptides and testosterone are scientifically related because some peptide signals participate in the regulation of the development-related hormonal system. This association is real, but it does not justify the general claim that peptides as a category increase testosterone.
Studies involving humans show effects in various directions.
In a small proof-of-concept study, kisspeptin-10 led to increases in LH and testosterone in men with type 2 diabetes and mild biochemical hypogonadism.[1] This result indicates that kisspeptin signaling can stimulate the reproductive axis under strictly defined experimental conditions.
Other studies, however, show a reverse pattern.
Longer exposure to the modified kisspeptin analog TAK-448 led to suppression of testosterone under certain conditions, whereas the peptide GnRH antagonist acyline reduced the levels of gonadotropins and testosterone in healthy young men [2] [3].
These results show why the word „peptide” cannot be considered synonymous with „testosterone booster”.
They also show why a short-term hormonal response should not be automatically interpreted as a result of a long-term one.
Even when testosterone actually increases, the second question remains: does the endocrine change lead to a significant clinical outcome?
The increase in testosterone in the serum itself does not necessarily indicate an improvement in libido, fertility, muscle mass, strength, athletic performance, body composition, mood, or general health.
Each of these results requires its own appropriate measurements and data from human studies.
Similarly, studies of growth hormone or IGF-1 should not be interpreted as evidence regarding testosterone. MK-677 is a non-peptide mimic of growth hormone, and studies in older people show why changes in lean body mass or growth hormone-related signaling should remain separate from claims regarding the reproductive system.[4]
The most justified interpretation of the studies regarding peptides and testosterone is therefore specific, not categorical.
This precise molecule, the biological target, the population, the exposure time, the type of hormone measurement, the clinical endpoint, the comparator, and the safety data determine what can actually be inferred from the study.
The mechanism, the laboratory response, the clinical benefit, fertility, sexual function, physical fitness, and safety are interrelated, but they are not interchangeable outcomes.
Disclaimer
The article is intended for educational and scientific informational purposes only. It does not constitute medical advice, diagnosis, or recommendations regarding the treatment of low testosterone levels, fertility advice, sports performance tips, information regarding the prescription of medications, dosage instructions, or recommendations for the use of any peptide, hormone-altering compound, experimental substance, or combination of such products.
The discussed hormonal results refer to specific molecules, preparations, populations, exposure conditions, measurements, and research projects. Short-term hormonal responses should not be automatically interpreted as evidence of lasting effects, and changes in testosterone or gonadotropin levels should not be considered as confirmation of improved fertility, libido, muscle growth, athletic performance, or general health status.
Questions regarding low testosterone levels, reproductive health, sexual function, fertility, endocrine disorders, or hormonal therapy require an individual assessment by a suitably qualified healthcare professional.
References
- George, J. T., Veldhuis, J. D., Tena-Sempere, M., Millar, R. P., & Anderson, R. A. (2013). Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism. Clinical endocrinology, 79(1), 100–104. https://doi.org/10.1111/cen.12103
- MacLean, D. B., Matsui, H., Suri, A., Neuwirth, R., & Colombel, M. (2014). Sustained exposure to the investigational Kisspeptin analog, TAK-448, down-regulates testosterone into the castration range in healthy males and in patients with prostate cancer: results from two phase 1 studies. The Journal of clinical endocrinology and metabolism, 99(8), E1445–E1453. https://doi.org/10.1210/jc.2013-4236
- Herbst, K. L., Coviello, A. D., Page, S., Amory, J. K., Anawalt, B. D., & Bremner, W. J. (2004). A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. The Journal of clinical endocrinology and metabolism, 89(12), 5959–5965. https://doi.org/10.1210/jc.2003-032123
- Nass, R., Pezzoli, S. S., Oliveri, M. C., Patrie, J. T., Harrell, F. E., Clasey, J. L., Heymsfield, S. B., Bach, M. A., Vance, M. L., & Thorner, M. O. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of internal medicine, 149(9), 601–611. https://doi.org/10.7326/0003-4819-149-9-200811040-00003
- Endocrine Society (2018, March 19). Testosterone therapy for hypogonadism guideline resources. Testosterone therapy for hypogonadism guideline resources
- Mills, E. G., Ertl, N., Wall, M. B., Thurston, L., Yang, L., Suladze, S., Hunjan, T., Phylactou, M., Patel, B., Muzi, B., Ettehad, D., Bassett, P. A., Howard, J., Rabiner, E. A., Bech, P., Abbara, A., Goldmeier, D., Comninos, A. N., & Dhillo, W. S. (2023). Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: A randomized clinical trial. JAMA network open, 6(2), e2254313. https://doi.org/10.1001/jamanetworkopen.2022.54313
- Jayasena, C. N., Nijher, G. M., Chaudhri, O. B., Murphy, K. G., Ranger, A., Lim, A., Patel, D., Mehta, A., Todd, C., Ramachandran, R., Salem, V., Stamp, G. W., Donaldson, M., Ghatei, M. A., Bloom, S. R., & Dhillo, W. S. (2009). Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis. The Journal of clinical endocrinology and metabolism, 94(11), 4315–4323. https://doi.org/10.1210/jc.2009-0406
- Adunsky, A., Chandler, J., Heyden, N., Lutkiewicz, J., Scott, B. B., Berd, Y., Liu, N., & Papanicolaou, D. A. (2011). MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of gerontology and geriatrics, 53(2), 183–189. https://doi.org/10.1016/j.archger.2010.10.004